CA Patent

CA3054403A1 — Inhibitors of bruton's tyrosine kinase

Assigned to Gilead Sciences Inc · Expires 2018-08-30 · 8y expired

What this patent protects

Provided are salts and crystalline forms of 6-amino-9-[(3R)-l-(2- butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one, compositions thereof, methods for their preparation, and methods for their use.

USPTO Abstract

Provided are salts and crystalline forms of 6-amino-9-[(3R)-l-(2- butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one, compositions thereof, methods for their preparation, and methods for their use.

Drugs covered by this patent

Patent Metadata

Patent number
CA3054403A1
Jurisdiction
CA
Classification
—
Expires
2018-08-30
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.